ALX Oncology Holdings Inc reports results for the quarter ended in December - Earnings Summary

ALX Oncology Holdings

08/03/2024 24:00

* ALX Oncology Holdings Inc  ALXO.OQ  reported a quarterly
adjusted loss of 93 cents​​ per share for the quarter ended in
December, lower than the same quarter last year, when the
company reported EPS of -75 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 84 cents per
share. Wall Street expected results to range from $-1.06 to -63
cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * ALX Oncology Holdings Inc's reported EPS for the quarter
was a
loss of 93 cents​.
    * The company reported a quarterly loss of $45.47 million.
    * ALX Oncology Holdings Inc shares had fallen by 0.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2.2%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ALX Oncology
Holdings Inc is $17.75 
This summary was machine generated from LSEG data March 8 at
12:00 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.84          -0.93          Missed
 Sep. 30 2023      -0.87          -1.24          Missed
 Jun. 30 2023      -0.88          -0.84          Beat
 Mar. 31 2023      -0.80          -0.74          Beat